AIMS: To characterise the genetic alterations in adult primary uterine rhabdomyosarcomas (uRMSs) and to investigate whether these tumours are genetically distinct from uterine carcinosarcomas (UCSs). METHODS AND RESULTS: Three tumours originally diagnosed as primary adult pleomorphic uRMS were subjected to massively parallel sequencing targeting 468 cancer-related genes and RNA-sequencing. Mutational profiles were compared with those of UCSs (n = 57) obtained from The Cancer Genome Atlas. Sequencing data analyses were performed using validated bioinformatic approaches. Pathogenic TP53 mutations and high levels of genomic instability were detected in the three cases. uRMS1 harboured a likely pathogenic YTHDF2-FOXR1 fusion. uRMS2 harboured a PPP2R1A hotspot mutation and amplification of multiple genes, including WHSC1L1, FGFR1, MDM2, and CCNE1, whereas uRMS3 harboured an FBXW7 hotspot mutation and an ANKRD11 homozygous deletion. Hierarchical clustering of somatic mutations and copy number alterations revealed that these tumours initially diagnosed as pleomorphic uRMSs and UCSs were similar. Subsequent comprehensive pathological re-review of the three uRMSs revealed previously unidentified minute pan-cytokeratin-positive atypical glands in one case (uRMS3), favouring its reclassification as UCS with extensive rhabdomyosarcomatous overgrowth. CONCLUSIONS: Adult pleomorphic uRMSs harbour TP53 mutations and high levels of copy number alterations. Our findings underscore the challenge in discriminating between uRMS and UCS with rhabdomyosarcomatous differentiation.
AIMS: To characterise the genetic alterations in adult primary uterine rhabdomyosarcomas (uRMSs) and to investigate whether these tumours are genetically distinct from uterine carcinosarcomas (UCSs). METHODS AND RESULTS: Three tumours originally diagnosed as primary adult pleomorphic uRMS were subjected to massively parallel sequencing targeting 468 cancer-related genes and RNA-sequencing. Mutational profiles were compared with those of UCSs (n = 57) obtained from The Cancer Genome Atlas. Sequencing data analyses were performed using validated bioinformatic approaches. Pathogenic TP53 mutations and high levels of genomic instability were detected in the three cases. uRMS1 harboured a likely pathogenic YTHDF2-FOXR1 fusion. uRMS2 harboured a PPP2R1A hotspot mutation and amplification of multiple genes, including WHSC1L1, FGFR1, MDM2, and CCNE1, whereas uRMS3 harboured an FBXW7 hotspot mutation and an ANKRD11 homozygous deletion. Hierarchical clustering of somatic mutations and copy number alterations revealed that these tumours initially diagnosed as pleomorphic uRMSs and UCSs were similar. Subsequent comprehensive pathological re-review of the three uRMSs revealed previously unidentified minute pan-cytokeratin-positive atypical glands in one case (uRMS3), favouring its reclassification as UCS with extensive rhabdomyosarcomatous overgrowth. CONCLUSIONS: Adult pleomorphic uRMSs harbour TP53 mutations and high levels of copy number alterations. Our findings underscore the challenge in discriminating between uRMS and UCS with rhabdomyosarcomatous differentiation.
Authors: Han Fang; Ewa A Bergmann; Kanika Arora; Vladimir Vacic; Michael C Zody; Ivan Iossifov; Jason A O'Rawe; Yiyang Wu; Laura T Jimenez Barron; Julie Rosenbaum; Michael Ronemus; Yoon-Ha Lee; Zihua Wang; Esra Dikoglu; Vaidehi Jobanputra; Gholson J Lyon; Michael Wigler; Michael C Schatz; Giuseppe Narzisi Journal: Nat Protoc Date: 2016-11-17 Impact factor: 13.491
Authors: Britta Weigelt; Rui Bi; Rahul Kumar; Pedro Blecua; Diana L Mandelker; Felipe C Geyer; Fresia Pareja; Paul A James; Fergus J Couch; Diana M Eccles; Fiona Blows; Paul Pharoah; Anqi Li; Pier Selenica; Raymond S Lim; Gowtham Jayakumaran; Nic Waddell; Ronglai Shen; Larry Norton; Hannah Y Wen; Simon N Powell; Nadeem Riaz; Mark E Robson; Jorge S Reis-Filho; Georgia Chenevix-Trench Journal: J Natl Cancer Inst Date: 2018-09-01 Impact factor: 13.506
Authors: Elisabetta Kuhn; Ren-Chin Wu; Bin Guan; Gang Wu; Jinghui Zhang; Yue Wang; Lei Song; Xiguo Yuan; Lei Wei; Richard B S Roden; Kuan-Tin Kuo; Kentaro Nakayama; Blaise Clarke; Patricia Shaw; Narciso Olvera; Robert J Kurman; Douglas A Levine; Tian-Li Wang; Ie-Ming Shih Journal: J Natl Cancer Inst Date: 2012-08-23 Impact factor: 13.506
Authors: Christopher T Saunders; Wendy S W Wong; Sajani Swamy; Jennifer Becq; Lisa J Murray; R Keira Cheetham Journal: Bioinformatics Date: 2012-05-10 Impact factor: 6.937
Authors: Simone Hettmer; Natasha M Archer; Gino R Somers; Ana Novokmet; Amy J Wagers; Lisa Diller; Carlos Rodriguez-Galindo; Lisa A Teot; David Malkin Journal: Cancer Date: 2013-12-30 Impact factor: 6.860
Authors: Siân Jones; Nicolas Stransky; Christine L McCord; Ethan Cerami; James Lagowski; Devon Kelly; Samuel V Angiuoli; Mark Sausen; Lisa Kann; Manish Shukla; Rosemary Makar; Laura D Wood; Luis A Diaz; Christoph Lengauer; Victor E Velculescu Journal: Nat Commun Date: 2014-09-19 Impact factor: 14.919
Authors: Jasmin Paris; Marcos Morgan; Joana Campos; Gary J Spencer; Alena Shmakova; Ivayla Ivanova; Christopher Mapperley; Hannah Lawson; David A Wotherspoon; Catarina Sepulveda; Milica Vukovic; Lewis Allen; Annika Sarapuu; Andrea Tavosanis; Amelie V Guitart; Arnaud Villacreces; Christian Much; Junho Choe; Ali Azar; Louie N van de Lagemaat; Douglas Vernimmen; Ali Nehme; Frederic Mazurier; Tim C P Somervaille; Richard I Gregory; Dónal O'Carroll; Kamil R Kranc Journal: Cell Stem Cell Date: 2019-04-25 Impact factor: 24.633
Authors: Giuseppe Narzisi; André Corvelo; Kanika Arora; Ewa A Bergmann; Minita Shah; Rajeeva Musunuri; Anne-Katrin Emde; Nicolas Robine; Vladimir Vacic; Michael C Zody Journal: Commun Biol Date: 2018-03-22